JAKAVI 15 MG 56 TB

Jakavi (generic name: Ruxolitinib) is a medication used to treat certain types of blood cancers, including myelofibrosis and polycythemia vera. It belongs to a class of drugs known as Janus kinase (JAK) inhibitors. Jakavi works by targeting specific enzymes involved in the signaling pathways that promote cell growth and inflammation.

How Jakavi Works

Mechanism of Action

1. Janus Kinase Inhibition:
   • Ruxolitinib inhibits the activity of Janus kinases (JAK1 and JAK2), which are enzymes involved in the signaling pathways of various cytokines and growth factors. By blocking these kinases, Jakavi disrupts the signaling processes that drive the abnormal cell proliferation and inflammation characteristic of myelofibrosis and polycythemia vera.
2. Reduction of Cytokine Activity:
   • By inhibiting JAK1 and JAK2, Jakavi reduces the activity of cytokines such as interleukins and interferons. This helps to decrease inflammation and abnormal cell growth.
3. Normalization of Blood Counts:
   • In conditions like myelofibrosis, Jakavi helps in normalizing blood counts and reducing symptoms like splenomegaly (enlarged spleen) and constitutional symptoms such as fever, night sweats, and weight loss.

Side Effects

Common Side Effects

• Headache:
  • Patients may experience headaches, which can often be managed with over-the-counter pain relievers.
• Diarrhea:
  • Gastrointestinal upset, including diarrhea, is a common side effect and can usually be managed with dietary adjustments and medications.
• Fatigue:
  • Fatigue is frequently reported and may require lifestyle changes and supportive care.
• Nausea:
  • Some individuals may experience nausea, which can be mitigated with antiemetic medications.
• Bruising:
  • Bruising or easy bleeding may occur due to the drug’s effect on blood cell counts.

Serious Side Effects

• Infections:
  • Jakavi may increase the risk of serious infections due to its immunosuppressive effects. Patients should be monitored for signs of infection and seek medical attention if symptoms occur.
• Liver Problems:
  • Liver function abnormalities, including increased liver enzymes, may occur and necessitate regular liver function tests.
• Anemia:
  • Patients may develop anemia, leading to symptoms such as weakness and dizziness. Blood counts should be monitored regularly.
• Elevated Lipid Levels:
  • Jakavi may cause increases in cholesterol and triglyceride levels, requiring monitoring and possible treatment.
• Gastrointestinal Bleeding:
  • In rare cases, gastrointestinal bleeding may occur, necessitating immediate medical evaluation.

Indications

Jakavi is indicated for:

• Myelofibrosis:
  • Used to treat adults with primary or secondary myelofibrosis who have symptomatic splenomegaly or other symptoms related to the disease.
• Polycythemia Vera:
  • Indicated for the treatment of polycythemia vera in patients who have an inadequate response to or are intolerant of hydroxyurea.

Contraindications

Jakavi should not be used in the following conditions:

• Hypersensitivity:
  • Known hypersensitivity to ruxolitinib or any of its components.
• Severe Liver Impairment:
  • Patients with severe liver impairment should avoid Jakavi due to the risk of exacerbating liver issues.
• Active Infections:
  • Use in patients with active infections is contraindicated due to the increased risk of worsening the infection.
• Pregnancy:
  • Jakavi is contraindicated during pregnancy due to potential harm to the fetus. Effective contraception is advised during treatment.
• Breastfeeding:
  • The use of Jakavi during breastfeeding is not recommended, as it may affect the infant.

Price in Different Countries

The price of Jakavi 15 mg tablets varies by country and healthcare system. Below is a table showing approximate price ranges in various countries.

Country	Price (Per 56 Tablets)	Reference
United States	$8,000 – $9,000	GoodRx
United Kingdom	£6,500 – £7,000	NHS UK
Canada	CAD $9,000 – $10,000	Health Canada
Australia	AUD $10,500 – $11,500	PBS Australia
India	₹6,00,000 – ₹7,00,000	Medlife

Top 5 Global Brands

1. Jakavi – Novartis:
   • The original manufacturer of ruxolitinib, known for its high quality and effectiveness in treating myelofibrosis and polycythemia vera.
2. Ruxolitinib – Mylan:
   • A prominent producer of generic ruxolitinib, providing a cost-effective alternative to Jakavi.
3. Ruxolitinib – Teva:
   • Another leading manufacturer of generic ruxolitinib, offering an affordable option for patients.
4. Ruxolitinib – Sandoz:
   • Provides a reliable generic version of ruxolitinib, adhering to stringent quality standards.
5. Ruxolitinib – Dr. Reddy’s Laboratories:
   • Known for producing high-quality generic ruxolitinib, ensuring accessibility for patients worldwide.